Enzymatica AB (publ)
STO:ENZY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (41.7), the stock would be worth kr-9.28 (434% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -12.5 | kr2.78 |
0%
|
| Industry Average | 41.7 | kr-9.28 |
-434%
|
| Country Average | 17.8 | kr-3.96 |
-243%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
E
|
Enzymatica AB (publ)
STO:ENZY
|
674.8m SEK | -12.5 | -13 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 30.4 | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
544.6B USD | 21.2 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.1 | 19.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.4B GBP | 22.8 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.8B CHF | 15.9 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
278.5B USD | 11.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.4 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 10.1 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.6B USD | 8.8 | 16.8 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 14 |
| Median | 17.8 |
| 70th Percentile | 23.3 |
| Max | 4 325.3 |
Other Multiples
Enzymatica AB (publ)
Glance View
Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
